BioCentury | Sep 17, 2020
Deals

Mirati and Boehringer partner to test KRAS-KRAS combo

...will test the G12C mutation-selective inhibitor MRTX849 from Mirati Therapeutics Inc. (NASDAQ:MRTX) in combination with BI 1701963...
...locking the mutant form of the protein in an inactive state (see “Amgen Banks on Speed”). BI 1701963...
...for activation (see “Boehringer Joins KRAS Race”). The idea behind the combination trial is that BI 1701963...
BioCentury | Oct 30, 2019
Preclinical News

Boehringer joins KRAS race with a molecule designed to block all mutations

...Boehringer announced Tuesday that its SOS1:KRAS inhibitor BI 1701963 started Phase I testing, making it the latest...
...Tuesday at the AACR-NCI-EORTC meeting in Boston. The data showed Boehringer’s tool compound BI-3406, a BI 1701963...
...has in vivo antitumor efficacy as a monotherapy and when combined with a MEK inhibitor. BI 1701963...
BioCentury | Oct 26, 2019
Product Development

How a KRAS program transformed Mirati's story

With the first clinical data due on Mirati’s KRAS inhibitor next week, the market will get its first chance to justify -- or otherwise -- the large chunk of the company’s $3 billion valuation tied...
Items per page:
1 - 3 of 3